Index removals and new products put Veeva Systems in focus

Veeva Systems (VEEV) has just been removed from several Russell growth indices, while at the same time rolling out new products in environmental, health, and safety and AI driven content review.

The recent index removals have come alongside a sharp rebound in Veeva Systems’ share price, with an 8.40% 1 day share price return and 11.88% 7 day share price return. However, the share price is still down 21.93% year to date and the 1 year total shareholder return is down 40.50%, pointing to a stock where short term momentum is improving while longer term performance remains weak.

If news around Veeva’s AI and compliance products has you reassessing the sector, this is a good moment to scan other healthcare focused AI opportunities using our curated 40 healthcare AI stocks

With Veeva Systems now trading at a discount to both a DCF estimate of intrinsic value and the average analyst price target, yet screening as slightly expensive on P/E, investors face a key question: is this a genuine mispricing, or is the market already paying up for future growth?

Most Popular Narrative: 30.2% Undervalued

With Veeva Systems last closing at $171.36 against a most followed fair value narrative of $245.48, the current gap is wide enough to make the underlying assumptions worth understanding.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.

Want to see what kind of revenue growth, margins, and future earnings multiple need to line up for that fair value to hold? The core narrative blends steady double digit growth assumptions with rising profitability and a richer earnings multiple that sits above the wider healthcare services peer group.

Result: Fair Value of $245.48 (UNDERVALUED)

However, this narrative for Veeva Systems still hinges on customers embracing new AI products, and on intense CRM competition not eroding pricing power or renewals.

Another View: What Veeva Systems’ P/E Is Telling You

While the SWS DCF model suggests Veeva Systems is trading at a discount to estimated future cash flows, the picture looks different when you focus on earnings. Veeva currently trades on a P/E of 29.6x versus 26.6x for the global Healthcare Services industry and a 27.9x fair ratio estimate.

In plain terms, the stock is priced above the wider industry and above where the fair ratio suggests the P/E could settle, even though it screens as cheaper than a 33.8x peer average. That mix of signals leaves a practical question for you: is this a margin of safety or a premium that needs stronger execution to hold up?

Next Steps

With sentiment on Veeva Systems clearly mixed, this is a good moment to move quickly, stress test the data yourself, and decide where you stand. For a clearer picture of what the market is optimistic about, review the 3 key rewards

Looking for more investment ideas beyond Veeva Systems?

If Veeva Systems has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh ideas that fit your style.

• Spot potential bargains early by scanning screener containing 19 high quality undiscovered gems that combine quality fundamentals with under the radar profiles.
• Prioritise resilience by reviewing 69 resilient stocks with low risk scores and focus on companies that score well on stability and downside protection.
• Target financial strength by checking solid balance sheet and fundamentals stocks screener (48 results) and concentrate on businesses that pair manageable debt with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.